JPMorgan stock slides 6.3% (NYSE:JPM)

]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

What to watch today: Stocks set to drop as Dow stock JPMorgan falls after quarterly results

]

BY THE NUMBERS

U.S. stock futures turned lower Friday after Dow stock JPMorgan (JPM) fell nearly 3% in the premarket as investors parsed quarterly results from the nation’s largest bank by assets. The company’s fourth-quarter per-share earnings of $3.33 and revenue of $30.35 billion, both beat estimates. However, JPMorgan said it took a $1.8 billion net benefit from releasing reserves for loan losses that never materialized; without that benefit earnings would have been $2.86 per share, missing expectations. (CNBC)

This week’s bounce in tech stocks was wiped out Thursday, sending the Nasdaq down 2.5% and the S&P 500 down 1.4%. The Dow Jones Industrial Average, which doesn’t have as much tech exposure, dropped 0.5%. All three benchmarks broke multiday winning streaks. The Nasdaq ended Thursday nearly 8.7% lower than its November all-time high, nearing correction territory. The S&P 500 and the Dow finished 3.3% and nearly 2.3%, respectively, away from their all-time highs last week. (CNBC) The government said December retail sales fell overall 1.9% and excluding autos dropped 2.3%, both were much lower than estimates for a 0.1% decline and 0.3% increase, respectively. The big drops came against a backdrop of shoppers spacing out holiday buying earlier this year due to supply chain concerns as inflation soared. (CNBC) Wells Fargo (WFC) on Friday posted better-than-expected fourth-quarter revenue of nearly $20.86 billion. Shares fell nearly 2% in the premarket. Results were helped by an $875 million reserve release that the bank had set aside during the Covid pandemic to safeguard against possible widespread loan losses. Wells Fargo also experienced 5% growth in loans from its consumer and commercial portfolios in the second half of 2021. (CNBC)

Citigroup (C) shares fell more than 3.5% on Friday after the banking giant reported a steep profit drop for the fourth quarter. The company’s net income dropped 26% to $3.2 billion. Citigroup cited an increase in expenses for the sharp decline. (CNBC)

IN THE NEWS TODAY

STOCKS TO WATCH

Bank Stocks: What’s Going on With JPM, WFC, BLK and C Today?

]

Bank Stocks: What’s Going on With JPM, WFC, BLK and C Today?

J.P. Morgan’s 2 Stock Picks With Over 80% Upside Potential

]

Less than two weeks into the new year, the key question is coming clear: should we buy the dip? The markets are swooning a bit, so far in January. Both the S&P 500 and the NASDAQ are registering losses in 2022’s cumulative trading sessions – 2% on the S&P, and 4.5% on the NASDAQ.

A combination of headwinds and tailwinds are pushing on equities. The former include the Omicron wave of COVID-19, as well as ongoing disruptions in the supply chains and labor markets. On the positive side, Omicron is looking both less dangerous and more contagious, leading to the possibility of mass natural immunity with less death, and marking an end in sight for the pandemic. And, the Federal Reserve is signaling that it will begin raising interest rates later this year. That move promises to put damper on rising inflation rates, with long-term benefits.

Overall, there is room for optimism, as pointed out by JPMorgan’s global markets strategist Marko Kolanovic: “We believe there is further upside for stocks and the dip driven by the Omicron scare should be bought into. The new variant is proving to be milder, and the adverse impact on mobility much more manageable.”

Turning to the general economic situation, Kolanovic adds, “Inventories are very low and the labor market is staying strong. We continue to see gains for earnings, and believe that consensus projections for 2022 will again prove too low.”

With this in mind, we wanted to take a closer look at two stocks that received JPMorgan’s stamp of approval, with the firm projecting upside potential of more than 80% for each. Using TipRanks’ database, we found out that the rest of the Street is also on board as both have earned a “Strong Buy” consensus rating.

Driven Brands Holdings (DRVN)

We’ll start with Driven Brands, North America’s largest automotive services company. Driven Brands is a holding company, operating a wide range of auto service locations through its subsidiaries. The services are offered in four divisions, including Maintenance; Paint, Collision, & Glass; Platform Services; and Carwash. Brands include well-known names such as Meineke, Take 5 Oil Change, Maaco, and Automotive Training Institute. There are over 4,200 brand locations, most owned and operated on a franchise basis.

Story continues

Driven held its IPO in January of last year, and raised over $650 million in net proceeds from the offering. The company’s stock has been volatile over the past year, but remains well above the initial pricing of $22.

Since the IPO, Driven has released four quarterly financial reports. Revenues rose through the summer; the Q3 result, of $371 million, was up 39% year-over-year, and same-store sales rose 12.8%. Adjusted earnings came in positive, at 26 cents per share, up by 30% yoy. The company added 53 stores during the third quarter.

This growth comes hand-in-hand with the economic reopening. As people get out and move around, they drive – and that means their cars will need maintenance and accessories. The company’s growth continued after Q3; since that quarterly release, the company has announced expansions in its carwash and auto glass segments. The company in November acquired its 100th car wash since August 2020, and now boasts over 300 car wash locations, while earlier this month Driven announced its acquisition of Auto Glass Now, with 75 locations in the auto glass repair segment.

JPMorgan’s 5-star analyst Christopher Horvers is bullish on DRVN for this year, writing of the stock: “We continue to see DRVN as one of the most differentiated stories in our coverage… DRVN checks many boxes in 2022 given: (1) supportive recovery dynamics (i.e., miles driven still below 2019 with congestion miles lagging), (2) pricing power largely offsetting cost inflation (labor and goods), (3) fewer competitors post-COVID, (4) material upside bias to estimates, (5) potential for structural valuation re-rating, and (6) a general defensive bias emphasizing perceived asset quality."

In line with his optimistic approach, Horvers gives DRVN shares an Overweight (i.e. Buy) rating and his $15 price target suggests an impressive ~83% potential upside for the coming year. (To watch Horvers’ track record, click here)

Overall, there are currently 4 analyst reviews of Driven Brands on record, and they all agree: this is a stock to Buy. This makes the Strong Buy consensus rating unanimous. DRVN shares are selling for $30.54, and their $45 average price target implies they have a one-year upside potential of ~47%. (See DRVN stock analysis on TipRanks)

Edgewise Therapeutics (EWTX)

The second stock we’ll look at is Edgewise Therapeutics, a clinical stage biopharma company with a focus on the treatment of musculoskeletal diseases. The company is developing orally dosed, small molecule novel therapies for rare muscle disorders with severe, debilitating effects. Targeted disorders include Duchenne and Becker muscular dystrophy (DMD and BMD), spasticity disorders, and neuromuscular metabolic disorders.

Most of Edgewise’s research tracks are still in preclinical testing, but the DMD/BMD program has reached Phase 1 clinical trials. Topline results from EDG-5506, a drug candidate in the muscle stabilizer class, were released earlier this month, and showed that the drug candidate was well tolerated in patients, with no adverse events occurring. The drug also showed significant achievement, beyond predicted levels, of muscle concentrations and reduced muscle damage biomarkers in adult BMD patients after two weeks of dosing. These are important positive results for a first-in-human clinical trial, and justify further trials with EDG-5506.

JPMorgan’s Tessa Romero describes the clinical trial data as a ‘win,’ noting: “In our view, key aspects that made the update a clear success include: 1) significant and time-dependent lowering of key muscle damage biomarkers; 2) favorable PK consistent with robust target engagement (e.g., achieving exposures exceeding pharmacologically active levels seen in diseased pre-clinical models, in both the plasma/muscle); and 3) noun expected safety/tolerability concerns.”

“With initial proof-of-concept (POC) data with EDG-5506 aided by both biological and functional markers of response in hand, we see the potential for substantial value creation over time on the potential of EDG-5506 alone, with a substantial platform to follow behind it,” Romero summed up.

In line with these comments, Romero lists Edgewise as a “top idea” for 2022. The JPMorgan analyst rates the stock an Overweight (i.e. Buy) along with a $33 price target. Should the target be met, a twelve-month gain in the shape of an 82% could be in store. (To watch Romero’s track record, click here)

All in all, Edgewise has a Strong Buy consensus rating, based on three analyst reviews given recently. The shares are trading for $18.10 and have an average price target of $32, implying an upside over the next 12 months of ~77%. (See EWTX stock analysis on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Breaking JPMorgan (JPM) Stock Price and Forecast : Earnings beat on EPS but revenue misses

]

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.